Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.